ClinicalTrials.gov

Results: 571



#Item
51BMJ 2013;347:f6104 doi: bmj.f6104 (Published 29 OctoberPage 1 of 9 Research

BMJ 2013;347:f6104 doi: bmj.f6104 (Published 29 OctoberPage 1 of 9 Research

Add to Reading List

Source URL: www.bmj.com

Language: English - Date: 2015-05-05 02:10:09
52Microsoft Word - Leaders in Clinical Transparency Corporate web page Feb 2015_updated 160215HC

Microsoft Word - Leaders in Clinical Transparency Corporate web page Feb 2015_updated 160215HC

Add to Reading List

Source URL: www.novartis.com

Language: English - Date: 2015-04-29 04:15:14
53Medicine / Pharmaceutical industry / Food and Drug Administration / Medical statistics / Clinical trials / Investigational New Drug / Investigational Device Exemption / ClinicalTrials.gov / Case report form / Research / Clinical research / Health

Office for Human Research Studies DANA-FARBER / HARVARD CANCER CENTER

Add to Reading List

Source URL: www.dfhcc.harvard.edu

Language: English - Date: 2015-04-28 08:42:30
54Policy Document Research (Trial Registration and Reporting) Policy Background The Australian Medical Students’ Association (AMSA) is the peak representative body for Australia’s 17,000 medical students. AMSA believes

Policy Document Research (Trial Registration and Reporting) Policy Background The Australian Medical Students’ Association (AMSA) is the peak representative body for Australia’s 17,000 medical students. AMSA believes

Add to Reading List

Source URL: media.amsa.org.au.s3.amazonaws.com

Language: English - Date: 2014-01-05 02:41:31
55Dear Senators/Representatives, The undersigned organizations, representing millions of Americans with rare and genetic diseases, advocates, industry, and academic institutions, write to express strong support for S. 139/

Dear Senators/Representatives, The undersigned organizations, representing millions of Americans with rare and genetic diseases, advocates, industry, and academic institutions, write to express strong support for S. 139/

Add to Reading List

Source URL: rarediseases.org

Language: English
56Dear Senators/Representatives, The undersigned organizations, representing millions of Americans with rare and genetic diseases, advocates, industry, and academic institutions, write to express strong support for S. 139/

Dear Senators/Representatives, The undersigned organizations, representing millions of Americans with rare and genetic diseases, advocates, industry, and academic institutions, write to express strong support for S. 139/

Add to Reading List

Source URL: www.rarediseases.org

Language: English - Date: 2015-03-03 13:54:50
57Key Questions to Ask Before Participating in a Clinical Trial Resources General

Key Questions to Ask Before Participating in a Clinical Trial Resources General

Add to Reading List

Source URL: www.accessexcellence.org

Language: English - Date: 2008-08-21 12:15:11
58Federal Register / Vol. 80, No[removed]Tuesday, March 31, [removed]Notices The Food and Drug Administration (FDA) is announcing a request for additional comments on the chemistry, manufacturing, and control (CMC) information

Federal Register / Vol. 80, No[removed]Tuesday, March 31, [removed]Notices The Food and Drug Administration (FDA) is announcing a request for additional comments on the chemistry, manufacturing, and control (CMC) information

Add to Reading List

Source URL: www.gpo.gov

Language: English - Date: 2015-03-31 08:02:18
59Federal Register / Vol. 80, No[removed]Tuesday, March 31, [removed]Notices Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Hypertension, Thrombosis, Vascular Inflammation and Dysfunct

Federal Register / Vol. 80, No[removed]Tuesday, March 31, [removed]Notices Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Hypertension, Thrombosis, Vascular Inflammation and Dysfunct

Add to Reading List

Source URL: www.gpo.gov

Language: English - Date: 2015-03-31 08:02:18
60Mesoblast Policy on Expanded Access Purpose To establish the Mesoblast policy for providing expanded access use of investigational medicinal products (IMP) to patients outside of a clinical trial. This policy applies glo

Mesoblast Policy on Expanded Access Purpose To establish the Mesoblast policy for providing expanded access use of investigational medicinal products (IMP) to patients outside of a clinical trial. This policy applies glo

Add to Reading List

Source URL: mesoblast.com

Language: English - Date: 2014-12-16 16:54:51